These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 7043971)

  • 21. In vivo immunosuppression induced by a virulent strain of Yersinia pseudotuberculosis.
    Simonet M; Berche P
    Ann Inst Pasteur Microbiol; 1986; 137B(2):207-10. PubMed ID: 3318867
    [No Abstract]   [Full Text] [Related]  

  • 22. [Chronic and lingering Yersinia ileitis].
    Parfenov AI; Chizhikova MD
    Ter Arkh; 2002; 74(12):77-80. PubMed ID: 12577849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Enteropathogenic Yersinia and host cytokine system].
    Zheleznikova GF; Bekhtereva MK
    Zh Mikrobiol Epidemiol Immunobiol; 2010; (6):112-21. PubMed ID: 21384597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Yersinia pseudotuberculosis polyarthritis].
    Raul P; Wiederkehr P; Faure G; Purel J; Gaucher A
    Rev Rhum Mal Osteoartic; 1980 Nov; 47(11):678. PubMed ID: 7003686
    [No Abstract]   [Full Text] [Related]  

  • 25. [Method for producing monoreceptor pseudotuberculosis sera].
    Tseneva GIa; Messorosh VG
    Lab Delo; 1983; (10):54-5. PubMed ID: 6196538
    [No Abstract]   [Full Text] [Related]  

  • 26. [The basic features of the pathogenesis of pseudotuberculosis (yersiniosis)].
    Avtsyn AP; Isachkova LM; Zhavoronkov AA; Somov GP; Makhnev MV
    Arkh Patol; 1990; 52(5):3-7. PubMed ID: 2204325
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A case of infection of Yersinia pseudotuberculosis associated with complement abnormalities.
    Yasuda M; Nakate S; Nobunaga M
    Fukuoka Igaku Zasshi; 1985 Jul; 76(7):399-405. PubMed ID: 3905549
    [No Abstract]   [Full Text] [Related]  

  • 28. [Yersinia lipopolysaccharide and its biological activity].
    Svarval' AV; Tseneva GIa; Shenderovich OA
    Zh Mikrobiol Epidemiol Immunobiol; 2006; (3):100-4. PubMed ID: 16830602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Presence of Yersinia specific antibodies in hospitalized patients with arthritis and Reiter syndrome.
    Constantiniu S; Chiriac R; Popovici N
    Arch Roum Pathol Exp Microbiol; 1989; 48(4):341-6. PubMed ID: 2520672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinico-immunologic indices in pseudotuberculosis (yersiniosis)].
    Volodina VN; Il'inskiĭ IuA
    Sov Med; 1987; (6):94-7. PubMed ID: 3306964
    [No Abstract]   [Full Text] [Related]  

  • 31. [Neutrophil damage test in Far Eastern scarlet-like fever (human pseudotuberculosis)].
    Timchenko NF; Dzadzieva MF; Malyĭ VP; Matiiash VV
    Lab Delo; 1982; (9):559-61. PubMed ID: 6183527
    [No Abstract]   [Full Text] [Related]  

  • 32. [Effect of phospholipid fractions from various bacteria and fungi on the immunity of mice to bacterial infections].
    Jakoniuk P; Borowski J
    Med Dosw Mikrobiol; 1980; 32(3):209-12. PubMed ID: 6782398
    [No Abstract]   [Full Text] [Related]  

  • 33. The role of V antigen in mice experimentally infected with Yersinia pseudotuberculosis; histopathological study using enzyme immunoassay.
    Sugiyama Y; Kaneko K; Takashima I; Hashimoto N
    Nihon Juigaku Zasshi; 1986 Aug; 48(4):781-9. PubMed ID: 3531653
    [No Abstract]   [Full Text] [Related]  

  • 34. [Pseudotuberculosis].
    Koroliuk AM; Tokarevich KN
    Tr Inst Im Pastera; 1976; 46():48-66. PubMed ID: 801304
    [No Abstract]   [Full Text] [Related]  

  • 35. [The epidemiology of Yersinia infections in the central taiga subzone of the eastern European plain].
    Vorontsova TA; Sel'kov IuA; Shchukina TN; Iushchenko GV
    Zh Mikrobiol Epidemiol Immunobiol; 1993; (3):35-9. PubMed ID: 8067089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical and immunological characteristics of the course of pseudotuberculous mixed infection associated with other diseases].
    Malyĭ VP
    Ter Arkh; 1980; 52(11):23-6. PubMed ID: 7008235
    [No Abstract]   [Full Text] [Related]  

  • 37. [Immunogenic and protective properties of nanosized constructs based on tubular immunostimulating complexes and pore forming protein of Yersinia pseudotuberculosis].
    Tsybul'skiĭ AV; Popov AM; Sanina NM; Mazeĭka AN; Portniagina OIu; Novikova OD; Timchenko NF; Kostetskiĭ ÉIa
    Zh Mikrobiol Epidemiol Immunobiol; 2011; (2):43-7. PubMed ID: 21598614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The serodiagnosis of human infections with Yersinia enterocolitica and Yersinia pseudotuberculosis.
    Chart H; Cheasty T
    FEMS Immunol Med Microbiol; 2006 Aug; 47(3):391-7. PubMed ID: 16872375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Yersinia enterocolitica and pseudotuberculosis reactive arthritis with antinuclear antibodies. 4 cases].
    Treves R; Arnaud M; Jacob P; Burki F; Desproges-Gotteron R
    Sem Hop; 1983 Jan; 59(2):122-3. PubMed ID: 6301030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Chief results of Far Eastern scarlatina-like fever (epidemic pseudotuberculosis) research].
    Somov GF
    Vestn Akad Med Nauk SSSR; 1980; (10):84-9. PubMed ID: 7001798
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.